Prot #R475-PN-1524: A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Moderate to Severe Chronic Low Back Pain

Project: Research project

Project Details

StatusFinished
Effective start/end date3/10/164/15/21

Funding

  • ICON Clinical Research, LLC (Prot #R475-PN-1524)
  • Regeneron Pharmaceuticals, Inc. (Prot #R475-PN-1524)